跳至主要内容
临床试验/NCT06605703
NCT06605703
已完成
4 期

The Comparative Effectiveness of Step-down Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide: A Randomized Controlled Trial (GLP1 Transition Trial)

WW International Inc1 个研究点 分布在 1 个国家目标入组 226 人2024年9月18日

概览

阶段
4 期
干预措施
Bupropion-Naltrexone-Metformin
疾病 / 适应症
Obesity
发起方
WW International Inc
入组人数
226
试验地点
1
主要终点
Percent body weight change at 12 weeks
状态
已完成
最后更新
19天前

概览

简要总结

The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.

注册库
clinicaltrials.gov
开始日期
2024年9月18日
结束日期
2026年2月5日
最后更新
19天前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
WW International Inc
责任方
Principal Investigator
主要研究者

Kara Marlatt

Sr Director, Scientific Research

WW International Inc

入排标准

入选标准

  • 18 years or older
  • Previous hx of BMI of \>30 or BMI of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease)
  • Currently taking Wegovy, Ozempic, Mounjaro or Zepbound and have been for at least 6 months
  • At least 15% body weight loss since taking Wegovy, Ozempic, Mounjaro, or Zepbound
  • Willing to stop taking their GLP-1 medication or is discontinuing due to circumstances such as access, cost, coverage, choice, or any other reason
  • Ability to provide informed consent prior to any trial-related activities
  • Able to read and write in English

排除标准

  • BMI \<22 kg/m2
  • Previous surgical obesity treatment
  • Currently pregnant or intending to become pregnant during the study
  • Breastfeeding
  • History of seizures or epilepsy
  • Current opioid use or in acute opioid withdrawal
  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs
  • History of glaucoma
  • Uncontrolled hypertension
  • Severe renal impairment and/or Chronic kidney disease stage III or GFR \<60

研究组 & 干预措施

WW Clinic + Meds v2

Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.

干预措施: Bupropion-Naltrexone-Metformin

WW Clinic - No medications

Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive no medications.

干预措施: WW Clinic

WW Clinic + Meds v1

Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.

干预措施: WW Clinic

WW Clinic + Meds v1

Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.

干预措施: Bupropion-Naltrexone

WW Clinic + Meds v2

Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.

干预措施: WW Clinic

结局指标

主要结局

Percent body weight change at 12 weeks

时间窗: Baseline, 12 weeks

Measurement of weight using a bluetooth body weight scale

次要结局

  • Change in body weight (in kg or pounds) at 12 weeks(Baseline, 12 weeks)
  • Physical Activity and Sedentary Behavior(Baseline, 12 weeks)
  • Dietary Intake(Baseline, 12 weeks)
  • Habit/Automaticity(Baseline, 12 weeks)
  • Hunger VAS (Visual Analogue Scale)(Baseline, 12 weeks)
  • Impact on Quality of Life(Baseline, 12 weeks)
  • Well-being(Baseline, 12 weeks)
  • Body Appreciation(Baseline, 12 weeks)
  • Self-Compassion(Baseline, 12 weeks)
  • Weight Bias(Baseline, 12 weeks)

研究点 (1)

Loading locations...

相似试验